Levetiracetam in the treatment of childhood epilepsy.
Epilepsy is a common pediatric neurologic disorder that is difficult to manage in a substantial portion of children. Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently been approved as add-on treatment for various seizure types in epilepsy populations that include children: for refractory partial seizures in epilepsy patients >/=4 years old, for myoclonic seizures in juvenile myoclonic epilepsy patients >/=12 years old, and for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy patients (>/=6 years old with FDA approval; >/=12 years old with EMEA approval). A review of published pediatric studies indicates that the efficacy of LEV is best established for partial seizures; however, results from recent double-blind and open-label trials indicate that adjunctive LEV also controls generalized seizures - particularly myoclonic and generalized tonic-clonic - in children and adolescents with primary generalized epilepsy. LEV was well-tolerated in pediatric studies. The most common adverse events (AEs) reported were sedation related. Behavioral AEs were among the most commonly reported events in some trials; conversely, improvements in behavior and cognition were also frequently reported. LEV appears to be a safe and effective AED with unique characteristics that benefit the treatment of children with epilepsy.
Wheless
James W
JW
Pediatric Neurology, University of Tennessee Health Science Center; Neuroscience Institute, LeBonheur Children's Medical Center, Memphis, TN, USA. jwheless@utmem.edu